user
menu
letter
Sign InRegister
langEnglisharrow

Anti-idiotypic Antibodies

Anti-idiotypic (Anti-ID) antibodies recognize unique epitopes in the variable region of a therapeutic antibody. In pharmacokinetic (PK) assays, they can be used as capture or detection reagents for drug-specific quantification in biological samples. For anti-drug antibody (ADA) assays, drug-specific anti-ID antibodies can provide positive controls for immunogenicity assay development and evaluation.

ACROBiosystems offers anti-idiotypic antibodies for a range of therapeutic antibodies, including adalimumab, rituximab, cetuximab, trastuzumab, and bevacizumab. Application data and assay protocols are available to support product selection and method development.

Anti-idiotypic Antibody Products List

Cat. No.TargetDrug NameProduct DescriptionOrder Now
TNF-α
TNF-α
Order
TNF-α
TNF-α
Order
TNF-α
TNF-α
Order
BCMA
BCMA
Order
BCMA
BCMA
Order
BCMA
BCMA
Order
BCMA
BCMA
Order
VEGF-A
VEGF-A
Order
VEGF-A
VEGF-A
Order
VEGF-A
VEGF-A
Order
VEGF-A
VEGF-A
Order
EGF R
EGF R
Order
EGF R
EGF R
Order
EGF R
EGF R
Order
EGF R
EGF R
Order
EGF R
EGF R
Order
TROP-2
TROP-2
Order
TROP-2
TROP-2
Order
TROP-2
TROP-2
Order
TROP-2
TROP-2
Order
Her2
Her2
Order
Her2
Her2
Order
Her2
Her2
Order
Nectin-4
Nectin-4
Order
Nectin-4
Nectin-4
Order
Her2
Her2
Order
Her2
Her2
Order
Her2
Her2
Order
Siglec-2
Siglec-2
Order
Siglec-2
Siglec-2
Order
Siglec-2
Siglec-2
Order
CD79B
CD79B
Order
CD79B
CD79B
Order
CD79B
CD79B
Order
CD20
CD20
Order
CD20
CD20
Order
CD20
CD20
Order
TROP-2
TROP-2
Order
TROP-2
TROP-2
Order
TROP-2
TROP-2
Order
Her2
Her2
Order
Her2
Her2
Order
Her2
Her2
Order

Two Key Applications

  • Application 1: Drug-Specific Quantification for PK Analysis
  • Application 2: Drug-Specific Positive Controls for ADA Assays

Application 1: Drug-Specific Quantification for PK Analysis

Assays that rely on generic anti-human IgG reagents may show elevated background in complex biological matrices because of interference from endogenous immunoglobulins. By recognizing the variable region of a specific therapeutic antibody, anti-idiotypic antibodies help distinguish the drug from endogenous IgG and can be used as capture reagents, detection reagents, or matched pairs.
Different analytes call for different types of anti-idiotypic antibodies:
Free drug: Antigen-blocking anti-idiotypic antibodies are used to detect unbound therapeutic antibody.
Total antibody drug: Antigen non-blocking anti-idiotypic antibodies can detect the therapeutic antibody across free and target-bound forms.
Target-bound drug: Antibodies that specifically recognize the therapeutic antibody–target complex are used to detect the bound form.
Rituximab PK Assay Case

Detection of rituximab by bridging ELISA in serum. Immobilized Anti-Rituximab Antibodies (Cat. No. RIB-Y37) at 2 μg/ml, added increasing concentrations of Rituximab (10% human serum) and then added biotinylated Anti-Rituximab Antibodies (Cat. No. RIB-BY35) at 1 μg/ml. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 1 ng/ml.

Request Protocol
Comparison of anti-idiotypic capture ELISA and anti-idiotypic bridging ELISA for rituximab detection in patient samples. Left: anti-idiotypic capture ELISA. Right: anti-idiotypic bridging ELISA.

Comparison between anti-idiotypic capture ELISA and anti-idiotypic bridging ELISA for rituximab detection in patient samples.Left: anti-idiotypic capture ELISA; Right: anti-idiotypic bridging ELISA.

Application 2: Drug-Specific Positive Controls for ADA Assays

ADA assays typically require a positive control tailored to the therapeutic being evaluated. Anti-idiotypic antibodies developed against that drug can serve as positive controls in bridging ELISA and MSD assays. Antibodies with confirmed neutralizing activity may also be used in neutralizing antibody assays
Anti-Rituximab Antibody in ADA Assays
The anti-rituximab antibody shown below was tested in both bridging ELISA and MSD formats. The bridging ELISA achieved a sensitivity of 9.7 ng/mL in 10% human serum, while the bridging MSD assay achieved a sensitivity of 0.97 ng/mL in 100% human serum.

Anti-Rituximab Antibodies bridging ELISA for Anti-Drug Antibody (ADA) assay development. Immobilized rituximab at 1 µg/ml, added increasing concentrations of Anti-Rituximab Antibodies (Cat. No. RIB-Y36, 10% human serum) and then added biotinylated rituximab at 2 µg/ml. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 9.7 ng/mL.

Request Protocol

Anti-Rituximab Antibodies bridging MSD for Anti-Drug Antibody (ADA) assay development. Added the mix solution (biotinylated Rituximab at 5 µg/mL, SULFO-Rituximab at 5Nµg/mL and increasing concentrations of Anti-Rituximab Antibodies (Cat. No. RIB-Y36, 100% human serum). Detection was performed using MSD Assay with a sensitivity of 0.97 ng/mL.

Request Protocol
Anti-Adalimumab Antibody in ADA Assays

Anti-Adalimumab Antibodies bridging ELISA for Anti-Drug Antibody (ADA) assay development. Immobilized adalimumab at 1 µg/ml, add increasing concentrations of Anti-Adalimumab Antibodies (Cat. No. ADB-Y19, 10% human serum) and then add biotinylated adalimumab at 5 µg/ml. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 0.6 ng/mL.

Request Protocol

Validation Data

Binding Affinity
SPR confirms binding between the anti-idiotypic antibody and its corresponding therapeutic antibody, providing affinity data for product selection and assay development.

Anti-Adalimumab Antibodies (mouse IgG1, Cat. No. ADB-Y19) captured on CM5 chip via anti-mouse antibodies surface, can bind human adalimumab with an affinity constant of 1.36 pM.

Request Protocol
Specificity Data
Cross-reactivity is assessed using the therapeutic antibody, its target, different IgG subclasses, and other antibodies of the same subclass to confirm drug-specific recognition.

Demonstration of the specificity of Anti-Cetuximab Antibodies (Cat. No. CEB-Y28) to the cetuximab.
 

Request Protocol
Stability Data
Accelerated and freeze-thaw studies are used to evaluate the stability of representative products.

Reconstituted Anti-Trastuzumab Antibodies were diluted to 0.4 mg/ml, aliquoted and placed at 37°C. Aliquots were removed from 37°C at every time and placed at 4°C along with the control. No significant loss of activity was observed.

Anti-Trastuzumab Antibodies were subjected to the indicated number of freeze-thaw cycles (FT). No significant loss of activity was observed.

Anti-Idiotypic Antibody Development Service

For projects not covered by off-the-shelf products, ACROBiosystems provides custom services spanning antigen preparation, monoclonal or polyclonal anti-idiotypic antibody development, and PK or immunogenicity assay kit development. These services can support programs involving monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, CAR-T therapies, and peptides.
Depending on the assay objective, custom programs can include antigen-blocking antibodies, antigen non-blocking antibodies, therapeutic antibody–target complex-specific antibodies, and matched antibody pairs. Polyclonal anti-idiotypic antibodies can also be developed as positive controls for ADA assays. Each program can be tailored to the therapeutic format, target analyte, and assay platform.

Learn About Anti-Idiotypic Antibody Development Services

FAQ

Q

How do ACROBiosystems anti-idiotypic antibody solutions support therapeutic antibody bioanalysis?

ACROBiosystems anti-idiotypic antibodies support ADA, neutralizing antibody, and PK assay development for therapeutic antibodies and ADCs. They may serve as positive controls or calibrators in ADA assays, functional reagents in neutralizing assays, and capture or detection reagents for therapeutic drug quantification. The portfolio includes unconjugated and biotinylated formats, with application recommendations and validation data provided for selected products.
Q

How do the requirements for anti-idiotypic antibodies differ between ADA and PK assays?

In ADA assays, an anti-idiotypic antibody is typically evaluated as a positive control or calibrator for monitoring assay sensitivity and performance. In PK assays, it must detect the administered therapeutic antibody in the relevant biological matrix and function in the intended capture or detection configuration. A clone recommended for one application should not be assumed to perform equivalently in another without assay-specific evaluation.
Q

What factors should be considered when selecting an anti-idiotypic antibody for ADA assay development?

A: Key factors include binding affinity and specificity, recognition of the therapeutic antibody's idiotype, compatibility with the assay format, and performance in relevant biological matrices. For ADA assays, a well-characterized anti-ID antibody with high specificity and suitable affinity is important for establishing reliable positive controls or calibrators.
Q

What should be considered when pairing anti-idiotypic antibodies for PK assays?

Pair development should consider specificity, affinity, epitope accessibility, assay orientation, and matrix effects. The same or different clones may be used depending on the therapeutic antibody and assay design. ACROBiosystems provides unconjugated and biotinylated antibodies with product-specific PK assay data for selected combinations.
Q

What validation data are available for ACROBiosystems anti-idiotypic antibodies?

Available data include SPR affinity and specificity testing, with MALS and stability characterization provided for selected products. These data can help identify suitable candidates for further assay development. Final performance should still be evaluated using the intended format, antibody pairing, and biological matrix.
Q

Which assay formats have been demonstrated with ACROBiosystems anti-idiotypic antibodies?

The page presents bridging ELISA and MSD assays for ADA detection, functional ELISA for neutralizing activity, and anti-idiotypic capture or bridging ELISA for PK analysis. These examples demonstrate selected antibodies under defined assay and serum conditions. Compatibility should be confirmed for each clone, matrix, and assay configuration.
Q

What custom solutions are available if no off-the-shelf anti-idiotypic antibody exists for a novel therapeutic lead or bispecific construct?

When catalog products do not cover novel CDR sequences, engineered bispecifics, or non-antibody scaffolds, custom development is necessary. ACROBiosystems’ Technical Service Platform offers one-stop Anti-Idiotypic Antibody Development Services. This includes antigen design, immunization, high-throughput hybridoma or single B cell discovery, SPR/BLI affinity ranking, SEC-MALS characterization, and custom PK/ADA kit development compliant with regulatory standards.
Q

What critical biophysical quality attributes make ACROBiosystems' anti-idiotypic antibodies highly reliable across multi-year clinical campaigns?

Multi-year clinical trials require reagents with unwavering batch consistency and minimal risk of assay drift. ACROBiosystems’ anti-idiotypic antibody portfolio features: Picomolar Affinity (KD): Characterized via Surface Plasmon Resonance (SPR), reaching picomolar binding strength (e.g., clone ADB-Y19 binds Adalimumab with an affinity constant of 1.36 pM). SEC-MALS Verification: Select clones undergo Size-Exclusion Chromatography coupled with Multi-Angle Light Scattering (SEC-MALS) to confirm purity and a defined monomeric molecular weight. High Thermal & Freeze-Thaw Stability: Validated through accelerated 37°C stress tests and repeated freeze-thaw cycles without activity loss.
  • Background
  • Anti-idiotypic Antibody Products List
  • Two Key Applications
  • Validation Data
  • Anti-Idiotypic Antibody Development Service
  • FAQ